Guardian Pharmacy Services, Inc. GRDN

Health CareFood & Drug RetailingUnited States of America

Last close 40.69 USD on Nov 1, 2026, +35.2% year to date

Quant rating

Quant rating A Rank 43 of 565 in Health Care

Growth C 357 of 565
Valuation B 151 of 565
Quality A 4 of 565
Revisions A 73 of 565
Momentum B 192 of 565

Wall Street consensus Strong Buy (1.43)Average target 48.51 USD +19.2%

Historical valuation

Multiples use consensus estimates for the next twelve months. The dashed line is the 5-year average.

Key data

Market cap: 2.6B
Enterprise value: 2.5B
52-week range: 26.84 – 48.33
3-year range: 16.00 – 48.33
Dividend yield: –
Beta (5 years): –
Shares outstanding: 63.3M
Next earnings: Nov 5, 2026

About the company

Guardian Pharmacy Services, Inc. is a pharmacy services company. The Company provides a range of technology-enabled services designed to help residents of long-term care facilities (LTCFs) adhere to drug regimen. It offers compliance packaging service for repackaging and dispensing prescription and non-prescription pharmaceuticals in accordance with physician orders and delivers the medications to LTCFs for administration to individual residents. It organizes each resident’s medications into individual unit dose or multi-unit dose packaging in accordance with specific drug distribution rounds that occur at LTCFs at specific times throughout the day. Its pharmacy workflow software helps to manage and track drug dispensing via a structured and scalable workflow process, including the use of barcode technology. It offers Guardian Compass, which includes dashboards created to help local pharmacies plan, track and optimize business operations.

Growth and profitability fiscal year ends December 31

Growth and profitability by fiscal year
	2025	2024	2023	2022	2021	5Y avg
Revenue (mil)	1,449	1,228	1,046	909	792	–
Revenue growth	17.9%	17.4%	15.1%	14.8%	7.6%	14.5%
EPS (basic, normalized)	0.78	−1.77	–	–	–	–
EPS growth	–	–	–	–	–	–
Gross margin	20.2%	19.9%	19.9%	20.4%	20.4%	20.2%
Net margin	3.4%	−9.0%	0.0%	3.9%	2.1%	0.1%
ROE	28.3%	−102.2%	67.4%	106.3%	52.3%	30.4%

Balance sheet, last quarter
Cash & short-term investments (mil)	89.8
Current ratio	1.65x
Long-term debt (mil)	0
Net debt (mil)	−77.8
Total equity (mil)	246
Net debt / equity	−0.32x
Net debt / EBITDA	−0.68x

Estimates and valuation

Consensus estimates and implied multiples
	Sales (mil)			EBITDA (mil)			EPS
Fiscal year	Mean est.	Growth	EV/Sales	Mean est.	Growth	EV/EBITDA	Mean est.	Growth	P/E
2025 actual	1,449	+17.9%	1.7x	115	+28.7%	21.7x	0.78	+144.1%	52.2x
2026	1,442	−0.5%	1.7x	130	+13.0%	19.2x	1.24	+58.7%	32.9x
2027	1,533	+6.3%	1.6x	141	+8.6%	17.7x	1.46	+17.8%	27.9x
2028	1,687	+10.0%	1.5x	155	+9.5%	16.2x	1.56	+6.9%	26.1x

Estimate revisions

Change in consensus estimates over 1, 3 and 6 months
	Sales				EPS
Fiscal year	Estimate (mil)	1M	3M	6M	Estimate	1M	3M	6M
2026	1,442	+0.3%	+2.0%	+2.0%	1.24	0.0%	+12.0%	+3.7%
2027	1,533	+0.3%	+0.7%	+1.2%	1.46	0.0%	+8.2%	+7.8%
2028	1,687	+0.6%	−0.2%	+1.8%	1.56	0.0%	+10.8%	+7.4%

Earnings surprises EPS beat in 2 of the last 4 quarters

Reported results versus consensus, last 10 fiscal quarters
Quarter ended	FQ-9	FQ-8	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Jun 2026
Sales reported (mil)	–	–	314	339	329	344	377	398	337	352
Sales mean (mil)	–	–	303	333	321	330	354	389	329	340
Surprise	–	–	+3.7%	+1.7%	+2.5%	+4.4%	+6.6%	+2.2%	+2.2%	+3.4%
EPS reported	–	–	−2.00	0.19	0.15	0.14	0.15	0.33	0.21	0.34
EPS mean	–	–	0.19	0.17	0.18	0.15	0.17	0.25	0.23	0.27
Surprise	–	–	−1,152.6%	+15.2%	−16.7%	−9.7%	−11.8%	+32.0%	−9.4%	+24.1%

Peer comparison Food & Drug Retailing

Peers in the same industry group, by market capitalization
Company	Market cap	Net debt/EBITDA	Net margin	P/B	FY1 P/E	FY2 P/E	FY1 EV/EBITDA	FY2 EV/EBITDA
GRDN Guardian Pharmacy Services, Inc.	2.6B	−0.68x	3.4%	10.49x	32.9x	27.9x	19.2x	17.7x
CLCGY Clicks Group Limited	3.0B	–	–	–	28.0x	25.9x	–	–
UNFI United Natural Foods Inc	2.8B	2.20x	0.3%	1.71x	13.6x	11.4x	5.7x	5.3x
ASAIY Sendas Distribuidora S.A.	2.0B	3.81x	0.6%	1.92x	6.1x	6.9x	4.4x	4.8x
NWC North West Company Inc	1.9B	1.13x	5.4%	3.24x	17.5x	15.5x	8.5x	7.8x
WMK Weis Markets, Inc.	1.8B	–	1.9%	1.33x	–	–	–	–
Mean		1.61x	2.3%	3.74x	19.6x	17.5x	9.5x	8.9x
Median		1.66x	1.9%	1.92x	17.5x	15.5x	7.1x	6.5x

Technical analysis

1M−0.1%
3M−2.8%
1Y+37.7%
3Y+154.3%

Financial statements in millions of USD

Income statement in millions of USD, fiscal years

Income statement, Guardian Pharmacy Services, Inc., fiscal years, most recent first
	2025	2024	2023	2022	2021	2020
Total revenue	1,449	1,228	1,046	909	792	736
Cost of revenue	1,156	984	838	723	631	589
Gross profit	293	244	208	186	161	147
Selling, general & administrative expenses	209	298	159	126	124	103
Research & development	–	–	–	–	–	–
Depreciation/amortization	10.7	9.4	8.7	7.5	7.3	11.5
Interest expense (income), operating	–	–	–	–	–	–
Unusual expense (income)	–	–	–	–	–	–
Other operating expenses	0	0	0	0	0	0
Operating income	72.7	−62.9	40.9	52.0	30.1	32.9
Net interest income (expense)	−0.7	−3.3	−2.9	−1.9	−1.6	−2.2
Gain (loss) on sale of assets	–	–	–	–	–	–
Other non-operating income (expense)	1.4	−0.3	−0.4	−0.4	−0.2	−1.1
Net income before taxes	73.4	−66.5	37.7	49.7	28.3	29.7
Provision for taxes	24.5	4.6	0	–	–	–
Minority interest	0.3	−16.3	−13.8	−14.2	−12.0	−9.7
Equity in affiliates	–	–	–	–	–	–
U.S. GAAP adjustment	–	–	–	–	–	–
Net income before extraordinary items	49.2	−87.3	23.9	35.4	16.3	19.9
Extraordinary items	–	–	–	–	–	–
Net income	49.2	−87.3	23.9	35.4	16.3	19.9
EBIT, normalized	72.7	−62.9	40.9	52.0	30.1	32.9
EBITDA, normalized	95.0	−43.1	59.2	68.6	46.7	50.2
Basic EPS, normalized	0.78	−1.77	–	–	–	–

Balance sheet in millions of USD, fiscal years

Balance sheet, Guardian Pharmacy Services, Inc., fiscal years, most recent first
	2025	2024	2023	2022	2021	2020
Assets
Cash & short-term investments	65.6	4.7	0.8	0.6	15.0	6.4
Receivables	102	97.2	77.3	67.8	55.2	48.7
Total inventory	43.4	40.5	36.7	41.4	33.1	31.9
Prepaid expenses	–	–	–	–	–	6.8
Other current assets	11.0	9.6	14.9	10.1	8.5	0
Total current assets	222	152	130	120	112	93.8
Property, plant & equipment	90.2	79.0	73.2	65.2	51.7	52.0
Goodwill	79.7	69.3	56.0	56.0	54.6	52.5
Intangibles	18.5	14.9	12.0	14.4	17.1	19.1
Long-term investments	–	–	–	–	–	–
Note receivable	–	–	–	–	–	–
Other long-term assets	2.6	5.7	0.4	0.4	0.5	0.5
Total assets	413	321	271	256	236	218
Liabilities
Accounts payable	116	102	85.6	78.1	64.6	53.4
Payable/accrued	–	–	–	–	–	–
Accrued expenses	22.2	21.3	23.2	19.5	20.5	26.6
Short-term debt	0	0	9.0	4.0	0	0
Current portion of long-term debt	3.9	3.8	7.9	6.8	6.0	5.7
Other current liabilities	18.4	16.7	12.3	3.6	20.4	0.7
Total current liabilities	161	144	138	112	112	86.4
Long-term debt	3.7	3.4	23.2	26.3	29.3	33.4
Minority interest	12.2	7.3	31.6	33.2	29.4	28.6
Other liabilities	30.3	23.3	50.1	41.9	41.7	31.1
Total liabilities	207	178	243	213	212	179
Shareholders' equity
Preferred stock	–	–	–	–	–	–
Common stock	0.1	0.1	0	0	0	0
Additional paid-in capital	139	125	–	–	–	–
Retained earnings (accumulated deficit)	66.3	17.1	–	–	–	–
Treasury stock	–	–	–	–	–	–
Other equity	0	0	28.2	42.7	23.9	38.5
Total equity	206	143	28.2	42.7	23.9	38.5
Total liabilities & shareholders' equity	413	321	271	256	236	218

Cash flow statement in millions of USD, fiscal years

Cash flow statement, Guardian Pharmacy Services, Inc., fiscal years, most recent first
	2025	2024	2023	2022	2021	2020
Operating activities
Net income	49.0	−71.0	37.7	49.7	28.3	29.7
Depreciation, depletion & amortization	22.3	19.8	18.2	16.6	16.5	17.3
Deferred taxes	3.1	–	–	–	–	–
Non-cash items	19.5	139	−0.7	1.0	15.1	6.8
Changes in working capital	6.4	−29.4	15.6	−18.7	−1.5	−1.1
Cash from operations	100	58.0	70.8	48.5	58.5	52.6
Investing activities
Capital expenditures	−19.5	−16.4	−14.6	−16.8	−9.3	−8.3
Other investing cash flows	−12.7	−14.0	1.1	−1.1	−3.9	−3.8
Cash from investing	−32.2	−30.4	−13.4	−17.9	−13.1	−12.2
Financing activities
Financing cash flow items	26.9	12.8	−54.3	−42.2	−30.7	−20.9
Cash dividends paid	–	–	–	–	–	–
Issuance (retirement) of debt, net	–	–	–	–	–	–
Other financing cash flows	−34.0	−36.5	−2.9	−2.8	−6.1	−13.4
Cash from financing	−7.1	−23.6	−57.2	−45.0	−36.8	−34.3
Foreign exchange effects	–	–	–	–	–	–
Net change in cash	61.0	3.9	0.1	−14.4	8.6	6.2
Free cash flow	80.7	41.6	56.3	31.8	49.2	44.3

Disclaimer

The financial data presented in this report is delayed and obtained from sources QDD Research believes to be reliable, including stock exchanges, SEDAR, and EDGAR. However, no representation or warranty is made as to the accuracy, completeness, or timeliness of the information. QDD Research accepts no liability for any errors, omissions, or financial losses arising from the use of this data.

This report is generated using a fully systematic and quantitative approach. All factor scores and the overall quant rating (ranging from D to A+) are derived from algorithmic models and are based solely on objective financial metrics. These scores are intended for informational purposes only and should not be interpreted as investment advice or a recommendation to buy, sell, or hold any securities.

QDD Research is not a registered investment advisor or broker-dealer and does not provide personalized financial advice. The content is not tailored to the specific investment goals, financial situation, or risk profile of any individual investor. We strongly encourage readers to consult with a licensed broker or investment advisor before making any investment decisions based on the information contained in this report.

Live quote provided by TradingView. Report data updated Nov 1, 2026 after market close.